Fluoxakalner

Fluoxakalner
Clinical data
Drug class	Kv7.2 and Kv7.3 potassium channel opener
Identifiers
	IUPAC name N-{4-[(4-fluorobenzyl)oxy]-2,6-dimethylphenyl}-2-phenylacetamide;
Chemical and physical data
Formula	C23H22FNO2
Molar mass	363.432 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC1C=CC(COC2C=C(C)C(N([H])C(=O)CC3C=CC=CC=3)=C(C)C=2)=CC=1;
	InChI InChI=1S/C23H22FNO2/c1-16-12-21(27-15-19-8-10-20(24)11-9-19)13-17(2)23(16)25-22(26)14-18-6-4-3-5-7-18/h3-13H,14-15H2,1-2H3,(H,25,26); Key:OAHSLLHOMXYHMH-UHFFFAOYSA-N;

Fluoxakalner is a K_v7.2 and K_v7.3 potassium channel opener which is under investigation for potential medical use.^[1] Its EC₅₀Tooltip half-maximal effective concentration for opening K_v7.2 and K_v7.3 channels has been found to be 360 nM.^[1] The drug produces analgesic effects in rodents and without causing sedation or locomotor changes.^[1] In addition, it did not inhibit various cardiac ion channels.^[1] The chemical synthesis of fluoxakalner has been described.^[1] Fluoxakalner was first described in the scientific literature by Wei Xiang and colleagues in 2026.^[1] It was developed as a replacement for retigabine, which was withdrawn from the market due to toxicity.^[1] Fluoxakalner avoids oxidative metabolites like retigabine's thought to be responsible for said toxicity.^[1]

References

1 2 3 4 5 6 7 8 Xiang W, Qu Y, Kong X, Yang Y, Hu F, Wang K, et al. (June 2026). "Discovery of fluoxakalner, a novel and preferential Kv7.2/7.3 channel opener for antinociception in mice". Bioorganic Chemistry. 180 110099. doi:10.1016/j.bioorg.2026.110099. PMID 42302653.

[XiangQuKong2026-1] 1 2 3 4 5 6 7 8 Xiang W, Qu Y, Kong X, Yang Y, Hu F, Wang K, et al. (June 2026). "Discovery of fluoxakalner, a novel and preferential Kv7.2/7.3 channel opener for antinociception in mice". Bioorganic Chemistry. 180 110099. doi:10.1016/j.bioorg.2026.110099. PMID 42302653.

[1]

See also

References